Clinical Trials Logo

Mantle Cell Lymphoma Refractory clinical trials

View clinical trials related to Mantle Cell Lymphoma Refractory.

Filter by:
  • None
  • Page 1

NCT ID: NCT05864742 Recruiting - Clinical trials for Mantle Cell Lymphoma Refractory

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Start date: September 7, 2023
Phase: Phase 2
Study type: Interventional

This is an open label, multi-centre, phase II study in which RR MCL patients will be genetically risk-stratified into Standard risk (no 9p21.1-24.3 loss, no SMARCA2 or SMARCA4 mut/del) and High risk (9p21.1-24.3 loss, SMARCA2 and/or SMARCA4 mut/del). Patients without the high-risk mutations will be treated with ibrutinib, rituximab and venetoclax. Patients with the high-risk mutations will be treated with ibrutinib, rituximab, venetoclax and navitoclax.

NCT ID: NCT05833763 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

GOlDiLOX
Start date: October 12, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and response of combining Pirtobrutinib and Glofitimab in patients with relapsed MCL. The main question it aims to answer are: - Will additive and synergistic effects be observed when using a combination of glofitamab and pirtobrutinib? - Will this combination be safe and lead to high complete- and remission rates with no residual disease? Pirtobrutinib will be given to all participants as an oral tablet for the duration of the entire study. Participants will receive other treatment in 3 phases: 1. Treatment Ramp-Up 1. Treatment with Obinutuzumab by Intravenous (IV) 2. An initial dose level of Glofitamab will evaluate step-up dosing. If excessive adverse events are observed, a lower initial dose will be used. 2. Fixed course combination phase: Treatment with Glofitamab by IV 3. Maintenance phase: Glofitamab is discontinued. 200mg oral daily

NCT ID: NCT05645744 Enrolling by invitation - Clinical trials for Diffuse Large B Cell Lymphoma

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Start date: September 29, 2021
Phase:
Study type: Observational

A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.

NCT ID: NCT05360238 Recruiting - Clinical trials for B-cell Lymphoma Refractory

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Start date: May 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

NCT ID: NCT01389427 Completed - Clinical trials for Mantle Cell Lymphoma Refractory

Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Start date: November 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open label, three arms, Phase IB study. A dose escalation phase of Temsirolimus (Toriselâ„¢) administered in intravenous (IV) at day 2, day 8 and day 15 in combination with three chemotherapies regimens for patients in relapsed/refractory Mantle Cell Lymphoma (MCL): - Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks for 6 cycles, - Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks for 6 cycles, - Rituximab-Aracytine high dose-Dexamethasone (R-DHA) administered every 4 weeks for 6 cycles.